TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks

TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The company reported revenue of $1.0 million versus $2.2 million in the prior-year quarter, reflecting lower research activity tied to its collaboration with Amgen. Research and development expenses totaled $21.9 million compared to $29.8 million a year earlier, while general and administrative expenses were $8.2 million versus $8.6 million, driven mainly by reduced professional costs and timing of spending.

The corporation’s net loss improved to $28.7 million from $34.1 million, supported by $0.5 million in net interest income compared with $2.1 million previously. Cash and cash equivalents stood at $128.1 million as of March 31, 2026, excluding $5.0 million restricted cash, with a runway expected into the second half of 2027. The update also outlined pipeline progress across heme malignancies, solid tumors, and autoimmune programs, including upcoming clinical milestones and preclinical developments.

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

In separate news, on April  27, TScan Therapeutics, Inc. (NASDAQ:TCRX) announced acceptance of a scientific abstract for presentation at the ASGCT 29th Annual Meeting in Boston, held May 11–15, 2026. The poster focuses on CD45-targeted TCR-T therapies aimed at eliminating residual disease and reducing relapse risk after allogeneic stem cell transplantation.

TScan Therapeutics, Inc. (NASDAQ:TCRX) is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered therapies for cancer and autoimmune diseases. It uses a proprietary platform to identify immune targets and design treatments that activate the body’s own T cells to fight disease.

While we acknowledge the risk and potential of TCRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TCRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1